JP2023540022A5 - - Google Patents

Info

Publication number
JP2023540022A5
JP2023540022A5 JP2023513271A JP2023513271A JP2023540022A5 JP 2023540022 A5 JP2023540022 A5 JP 2023540022A5 JP 2023513271 A JP2023513271 A JP 2023513271A JP 2023513271 A JP2023513271 A JP 2023513271A JP 2023540022 A5 JP2023540022 A5 JP 2023540022A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
polypeptide
car
recombinant nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540022A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/073369 external-priority patent/WO2022043315A1/en
Publication of JP2023540022A publication Critical patent/JP2023540022A/ja
Publication of JP2023540022A5 publication Critical patent/JP2023540022A5/ja
Pending legal-status Critical Current

Links

JP2023513271A 2020-08-24 2021-08-24 チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにＣＤ４４ｖ６を認識するＣＡＲ発現細胞 Pending JP2023540022A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20192399.2 2020-08-24
EP20192399 2020-08-24
EP20205696 2020-11-04
EP20205696.6 2020-11-04
PCT/EP2021/073369 WO2022043315A1 (en) 2020-08-24 2021-08-24 A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6

Publications (2)

Publication Number Publication Date
JP2023540022A JP2023540022A (ja) 2023-09-21
JP2023540022A5 true JP2023540022A5 (https=) 2024-09-02

Family

ID=77710751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513271A Pending JP2023540022A (ja) 2020-08-24 2021-08-24 チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにＣＤ４４ｖ６を認識するＣＡＲ発現細胞

Country Status (5)

Country Link
US (1) US20240009310A1 (https=)
EP (1) EP4199959A1 (https=)
JP (1) JP2023540022A (https=)
AU (1) AU2021334107A1 (https=)
WO (1) WO2022043315A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021334950A1 (en) * 2020-08-24 2023-03-02 Charité - Universitätsmedizin Berlin Chimeric antigen receptor (CAR)-expressing cells recognizing CEA
CN116496398B (zh) * 2022-10-31 2023-10-31 南京元迈细胞生物科技有限公司 一种特异性结合CD44的v5外显子的抗体及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
ATE466948T1 (de) 1997-03-11 2010-05-15 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
AU751647B2 (en) 1998-05-26 2002-08-22 Innogenetics N.V. Method for expanding primate B cells selectively in immunocompromised mice and producing large numbers of antigen-specific B lymphocytes for the production of primate monoclonal antibodies
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2160461B1 (en) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Hyperactive variants of the transposase protein of the transposon system sleeping beauty
JP2018510652A (ja) * 2015-03-18 2018-04-19 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Ｈｅｒ２／ｅｒｂｂ２キメラ抗原受容体
CA2997551A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
EP3592368A1 (en) * 2017-03-08 2020-01-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
EP3612210A4 (en) * 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
EP3743445A1 (en) * 2018-01-26 2020-12-02 City of Hope Chimeric antigen receptors and methods for reducing off target toxicity
EP3784256A4 (en) * 2018-04-27 2022-06-29 Baylor College of Medicine Car t cells with one or more interleukins

Similar Documents

Publication Publication Date Title
JP7755890B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP7297807B2 (ja) 抗突然変異ｋｒａｓ ｔ細胞受容体
US20220275052A1 (en) Receptor
JP2022109953A5 (https=)
JP2022169543A (ja) 改善された養子ｔ細胞療法
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
JP2018523484A (ja) 細胞
CN109280086B (zh) 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体
CN113968913A (zh) 抗cd70嵌合抗原受体
JP2021525534A5 (https=)
US20250197470A1 (en) Pooling signaling and costimulatory domains in b7h6 chimeric antigen receptor
US20200239545A1 (en) Receptor
JP2022527267A5 (https=)
Lo et al. Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor
CN114867490A (zh) 细胞因子调控表达的免疫效应细胞
CN114929863B (zh) 共表达趋化因子受体的免疫效应细胞
CN111892661A (zh) 一种嵌合抗原受体及其在制备治疗肿瘤的产品中的应用
JP2023540022A5 (https=)
WO2022029431A1 (en) Chimeric receptor binding tgf-beta
AU2021269889A1 (en) Method
WO2025176000A1 (zh) 一种识别kras突变的t细胞受体及其编码序列
JP6666342B2 (ja) 抗サイログロブリンｔ細胞レセプター
JP2023540023A5 (https=)
JP2022526194A (ja) Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法
KR20250174161A (ko) 엔도글린 및 메소테린 이중 항원 표적 car 및 이의 용도